A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma

The clinical course of patients with uterine leiomyosarcoma (LMS) is difficult to predict with the currently available categorical staging systems of the American Joint Committee on Cancer (AJCC) and the International Federation of Gynecology and Obstetrics (FIGO). The objective of the current study was to develop and validate a novel, clinically relevant, individualized prognostic model for patients with uterine LMS.

[1]  M. Kattan.  Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer , 2003, Current opinion in urology.

[2]  Z. Petrovich,et al.  Treatment of uterine sarcomas , 1990, Cancer.

[3]  R. Barakat,et al.  Incidence of lymph node and ovarian metastases in leiomyosarcoma of the uterus. , 2003, Gynecologic oncology.

[4]  L. Jacks,et al.  Stage-specific outcomes of patients with uterine leiomyosarcoma: a comparison of the international Federation of gynecology and obstetrics and american joint committee on cancer staging systems. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D Spiegelman,et al.  Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. , 2001, Journal of the National Cancer Institute.

[6]  A. Kaider,et al.  Leiomyosarcoma of the uterus: a clinicopathologic multicenter study of 71 cases. , 1999, Gynecologic oncology.

[7]  R. Mannel,et al.  Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. , 2008, Gynecologic oncology.

[8]  P. Sabbatini,et al.  Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. , 2009, Gynecologic oncology.

[9]  M. Gonen,et al.  Concordance probability and discriminatory power in proportional hazards regression , 2005 .

[10]  P. Rose,et al.  Adjuvant therapy for stage I uterine sarcoma. , 1987, American journal of obstetrics and gynecology.

[11]  A. Berchuck,et al.  Treatment of Uterine Leiomyosarcoma , 1988, Obstetrics and gynecology.

[12]  Mithat Gonen,et al.  Individualized prediction of colon cancer recurrence using a nomogram. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Olshen,et al.  Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma , 2004, Cancer.

[14]  Murray F. Brennan,et al.  Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas , 2004, Annals of surgery.

[15]  M. Kattan,et al.  Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  M. Kattan,et al.  Postoperative nomogram for 12-year sarcoma-specific death. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Raj,et al.  How to build and interpret a nomogram for cancer prognosis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Collin,et al.  Prognostic Factors in Early-Stage Leiomyosarcoma of the Uterus , 2009, International Journal of Gynecologic Cancer.

[19]  A. Worth.  Role of the pathologist in the management of soft-tissue sarcomas. , 1988, Canadian journal of surgery. Journal canadien de chirurgie.

[20]  P. Thall,et al.  Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Soslow.  Uterine mesenchymal tumors: a review of selected topics , 2008 .

[22]  P. Rose,et al.  Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. , 2008, Gynecologic oncology.

[23]  J. Prat.  FIGO staging for uterine sarcomas , 2009, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[24]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[25]  E. Oliva,et al.  The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital. , 2004, Gynecologic oncology.

[26]  M. Kattan,et al.  Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  D. Metzinger,et al.  Diagnostic criteria for uterine smooth muscle tumors: leiomyoma variants associated with malignant behavior. , 2007, The Journal of reproductive medicine.

[28]  J. Nesland,et al.  Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients , 2009, Histopathology.

[29]  Michael W Kattan,et al.  Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Eastham,et al.  Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. , 2003, Urology.

[31]  S. Cha,et al.  Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. , 2003, Gynecologic oncology.

[32]  M. Franchi,et al.  Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). , 2008, European journal of cancer.

[33]  M. Piver,et al.  Patterns of metastasis in uterine sarcoma. An autopsy study. , 1989, Cancer.

[34]  C. Sternberg,et al.  Are nomograms better than currently available stage groupings for bladder cancer? , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  B. Sorbe,et al.  Prophylactic pelvic irradiation as part of primary therapy in uterine sarcomas. , 2008, International journal of oncology.

[36]  J. Berek,et al.  Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. , 2008, American journal of obstetrics and gynecology.

[37]  N. Weiss,et al.  The epidemiology of sarcomas of the uterus. , 1986, Journal of the National Cancer Institute.

[38]  F. Saad,et al.  A nomogram predicting 10-year life expectancy in candidates for radical prostatectomy or radiotherapy for prostate cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Manola,et al.  Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma. , 2009, European journal of cancer.

[40]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Kempson,et al.  Problematic Uterine Smooth Muscle Neoplasms: A Clinicopathologic Study of 213 Cases , 1994, The American journal of surgical pathology.

[42]  Daniel B. Mark,et al.  TUTORIAL IN BIOSTATISTICS MULTIVARIABLE PROGNOSTIC MODELS: ISSUES IN DEVELOPING MODELS, EVALUATING ASSUMPTIONS AND ADEQUACY, AND MEASURING AND REDUCING ERRORS , 1996 .

[43]  C. Mangan,et al.  A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.